The effect of genetic variability on drug response in conventional breast cancer treatment

European Journal of Pharmacology

Volumn 625, Issue 1-3, 2009, Pages 122-130

  Wiechec, Emilia ^a   Hansen, Lise Lotte ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

Breast cancer; Chemotherapy; Drug response; Personalized medicine; SNP

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANASTROZOLE; CAPECITABINE; CARBOPLATIN; CARBOXYLESTERASE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTIDINE DEAMINASE; CYTOCHROME P450; DIHYDROPYRIMIDINE DEHYDROGENASE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; GLUTATHIONE TRANSFERASE P1; IRINOTECAN; LETROZOLE; METHOTREXATE; MITOMYCIN; PACLITAXEL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); RIBONUCLEOTIDE REDUCTASE; SULFOTRANSFERASE 1A1; TAMOXIFEN; THYMIDYLATE SYNTHASE;

BONE MARROW SUPPRESSION; BREAST CANCER; CANCER RESISTANCE; COLON CANCER; COLORECTAL CANCER; DIARRHEA; DISEASE FREE SURVIVAL; DNA REPAIR; DNA SYNTHESIS; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; DRUG TRANSPORT; GENETIC RISK; GENETIC VARIABILITY; HAND FOOT SYNDROME; HUMAN; LEUKEMIA; LEUKOPENIA; LYMPHOMA; MISSENSE MUTATION; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; NONSENSE MUTATION; OVERALL SURVIVAL; PHARMACOGENETICS; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIATION INJURY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 71649116290     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.08.045     Document Type: Review

References (111)

1. Ambrosone C.B., Ahn J., Singh K.K., Rezaishiraz H., Furberg H., Sweeney C., Coles B., and Trovato A. Polymorphisms in genes related to oxidative stress (MPO, MnSOD, CAT) and survival after treatment for breast cancer. Cancer Res. 65 (2005) 1105-1111
2. Andreassen C.N., Alsner J., Overgaard M., and Overgaard J. Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. Radiother. Oncol. 69 (2003) 127-135
3. Andreassen C.N., Alsner J., Overgaard J., Herskind C., Haviland J., Owen R., Homewood J., Bliss J., and Yarnold J. TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. Radiother. Oncol. 75 (2005) 18-21
4. Andreassen C.N., Alsner J., Overgaard M., Sorensen F.B., and Overgaard J. Risk of radiation-induced subcutaneous fibrosis in relation to single nucleotide polymorphisms in TGFB1, SOD2, XRCC1, XRCC3, APEX and ATM-a study based on DNA from formalin fixed paraffin embedded tissue samples. Int. J. Radiat. Biol. 82 (2006) 577-586
5. Andreassen C.N., Overgaard J., Alsner J., Overgaard M., Herskind C., Cesaretti J.A., Atencio D.P., Green S., Formenti S.C., Stock R.G., and Rosenstein B.S. ATM sequence variants and risk of radiation-induced subcutaneous fibrosis after postmastectomy radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 64 (2006) 776-783
6. Barzilay G., and Hickson I.D. Structure and function of apurinic/apyrimidinic endonucleases. BioEssays 17 (1995) 713-719
7. Bewick M.A., Conlon M.S., and Lafrenie R.M. Polymorphisms in manganese superoxide dismutase, myeloperoxidase and glutathione-S-transferase and survival after treatment for metastatic breast cancer. Breast Cancer Res. Treat. 111 (2008) 93-101
8. Boyle P., and Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann. Oncol. 16 (2005) 481-488
9. Boyle P., and Ferlay J. Mortality and survival in breast and colorectal cancer. Nat. Clin. Pract. Oncol. 2 (2005) 424-425
10. Brueggemeier R.W. Aromatase inhibitors: new endocrine treatment of breast cancer. Semin. Reprod. Med. 22 (2004) 31-43
11. Cardis E., Krewski D., Boniol M., Drozdovitch V., Darby S.C., Gilbert E.S., Akiba S., Benichou J., Ferlay J., Gandini S., Hill C., Howe G., Kesminiene A., Moser M., Sanchez M., Storm H., Voisin L., and Boyle P. Estimates of the cancer burden in Europe from radioactive fallout from the Chernobyl accident. Int. J. Cancer 119 (2006) 1224-1235
12. Chabner B.A., Donehower R.C., and Schilsky R.L. Clinical pharmacology of methotrexate. Cancer Treat. Rep. 65 Suppl 1 (1981) 51-54
13. Chang T.K., Weber G.F., Crespi C.L., and Waxman D.J. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res. 53 (1993) 5629-5637
14. Chang-Claude J., Popanda O., Tan X.L., Kropp S., Helmbold I., von Fournier D., Haase W., Sautter-Bihl M.L., Wenz F., Schmezer P., and Ambrosone C.B. Association between polymorphisms in the DNA repair genes, XRCC1, APE1, and XPD and acute side effects of radiotherapy in breast cancer patients. Clin. Cancer Res. 11 (2005) 4802-4809
15. Code E.L., Crespi C.L., Penman B.W., Gonzalez F.J., Chang T.K., and Waxman D.J. Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab. Dispos. 25 (1997) 985-993
16. Coles B.F., and Kadlubar F.F. Detoxification of electrophilic compounds by glutathione S-transferase catalysis: determinants of individual response to chemical carcinogens and chemotherapeutic drugs?. BioFactors 17 (2003) 115-130
17. Collie-Duguid E.S., Etienne M.C., Milano G., and McLeod H.L. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 10 (2000) 217-223
18. Colomer R., Monzo M., Tusquets I., Rifa J., Baena J.M., Barnadas A., Calvo L., Carabantes F., Crespo C., Munoz M., Llombart A., Plazaola A., Artells R., Gilabert M., Lloveras B., and Alba E. A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. Clin. Cancer Res. 14 (2008) 811-816
19. Costanzi S., Vincenzetti S., Vita A., Lambertucci C., Taffi S., Volpini R., Vittori S., and Cristalli G. Human cytidine deaminase: understanding the catalytic mechanism. Nucleosides Nucleotides Nucleic Acids 22 (2003) 1539-1543
20. David Josephy P., Peter Guengerich F., and Miners J.O. "Phase I and Phase II" drug metabolism: terminology that we should phase out?. Drug Metab. Rev. 37 (2005) 575-580
21. Dean M., Rzhetsky A., and Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 11 (2001) 1156-1166
22. Dey S. Single nucleotide polymorphisms in human P-glycoprotein: its impact on drug delivery and disposition. Expert Opin. Drug Deliv. 3 (2006) 23-35
23. Edwards Y.H., Potter J., and Hopkinson D.A. Human FAD-dependent NAD(P)H diaphorase. Biochem. J. 187 (1980) 429-436
24. Fagerholm R., Hofstetter B., Tommiska J., Aaltonen K., Vrtel R., Syrjakoski K., Kallioniemi A., Kilpivaara O., Mannermaa A., Kosma V.M., Uusitupa M., Eskelinen M., Kataja V., Aittomaki K., von Smitten K., Heikkila P., Lukas J., Holli K., Bartkova J., Blomqvist C., Bartek J., and Nevanlinna H. NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat. Genet. 40 (2008) 844-853
25. Falany C.N., Wheeler J., Oh T.S., and Falany J.L. Steroid sulfation by expressed human cytosolic sulfotransferases. J. Steroid Biochem. Mol. Biol. 48 (1994) 369-375
26. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., and Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 18 (2007) 581-592
27. Frazer K.A., Ballinger D.G., Cox D.R., Hinds D.A., Stuve L.L., Gibbs R.A., Belmont J.W., Boudreau A., Hardenbol P., Leal S.M., Pasternak S., Wheeler D.A., Willis T.D., Yu F., Yang H., Zeng C., Gao Y., Hu H., Hu W., Li C., Lin W., Liu S., Pan H., Tang X., Wang J., Wang W., Yu J., Zhang B., Zhang Q., Zhao H., Zhou J., Gabriel S.B., Barry R., Blumenstiel B., Camargo A., Defelice M., Faggart M., Goyette M., Gupta S., Moore J., Nguyen H., Onofrio R.C., Parkin M., Roy J., Stahl E., Winchester E., Ziaugra L., Altshuler D., Shen Y., Yao Z., Huang W., Chu X., He Y., Jin L., Liu Y., Sun W., Wang H., Wang Y., Xiong X., Xu L., Waye M.M., Tsui S.K., Xue H., Wong J.T., Galver L.M., Fan J.B., Gunderson K., Murray S.S., Oliphant A.R., Chee M.S., Montpetit A., Chagnon F., Ferretti V., Leboeuf M., Olivier J.F., Phillips M.S., Roumy S., Sallee C., Verner A., Hudson T.J., Kwok P.Y., Cai D., Koboldt D.C., Miller R.D., Pawlikowska L., Taillon-Miller P., Xiao M., Tsui L.C., Mak W., Song Y.Q., Tam P.K., Nakamura Y., Kawaguchi T., Kitamoto T., Morizono T., Nagashima A., Ohnishi Y., Sekine A., Tanaka T., Tsunoda T., Deloukas P., Bird C.P., Delgado M., Dermitzakis E.T., Gwilliam R., Hunt S., Morrison J., Powell D., Stranger B.E., Whittaker P., Bentley D.R., Daly M.J., de Bakker P.I., Barrett J., Chretien Y.R., Maller J., McCarroll S., Patterson N., Pe'er I., Price A., Purcell S., Richter D.J., Sabeti P., Saxena R., Schaffner S.F., Sham P.C., Varilly P., Stein L.D., Krishnan L., Smith A.V., Tello-Ruiz M.K., Thorisson G.A., Chakravarti A., Chen P.E., Cutler D.J., Kashuk C.S., Lin S., Abecasis G.R., Guan W., Li Y., Munro H.M., Qin Z.S., Thomas D.J., McVean G., Auton A., Bottolo L., Cardin N., Eyheramendy S., Freeman C., Marchini J., Myers S., Spencer C., Stephens M., Donnelly P., Cardon L.R., Clarke G., Evans D.M., Morris A.P., Weir B.S., Mullikin J.C., Sherry S.T., Feolo M., Skol A., Zhang H., Matsuda I., Fukushima Y., Macer D.R., Suda E., Rotimi C.N., Adebamowo C.A., Ajayi I., Aniagwu T., Marshall P.A., Nkwodimmah C., Royal C.D., Leppert M.F., Dixon M., Peiffer A., Qiu R., Kent A., Kato K., Niikawa N., Adewole I.F., Knoppers B.M., Foster M.W., Clayton E.W., Watkin J., Muzny D., Nazareth L., Sodergren E., Weinstock G.M., Yakub I., Birren B.W., Wilson R.K., Fulton L.L., Rogers J., Burton J., Carter N.P., Clee C.M., Griffiths M., Jones M.C., McLay K., Plumb R.W., Ross M.T., Sims S.K., Willey D.L., Chen Z., Han H., Kang L., Godbout M., Wallenburg J.C., L'Archeveque P., Bellemare G., Saeki K., An D., Fu H., Li Q., Wang Z., Wang R., Holden A.L., Brooks L.D., McEwen J.E., Guyer M.S., Wang V.O., Peterson J.L., Shi M., Spiegel J., Sung L.M., Zacharia L.F., Collins F.S., Kennedy K., Jamieson R., and Stewart J. A second generation human haplotype map of over 3.1 million SNPs. Nature 449 (2007) 851-861
28. Fromm M.F. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv. Drug Deliv. Rev. 54 (2002) 1295-1310
29. Gehrmann M., Schmidt M., Brase J.C., Roos P., and Hengstler J.G. Prediction of paclitaxel resistance in breast cancer: is CYP1B1*3 a new factor of influence?. Pharmacogenomics 9 (2008) 969-974
30. George G., Wynne H.A., and Woodhouse K.W. The association of age with the induction of drug-metabolizing enzymes in human monocytes. Age Ageing 19 (1990) 364-367
31. Gibson L.J., Dawson C.K., Lawrence D.H., and Bliss J.M. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst. Rev. (2007) CD003370
32. Gilbert J.A., Salavaggione O.E., Ji Y., Pelleymounter L.L., Eckloff B.W., Wieben E.D., Ames M.M., and Weinshilboum R.M. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin. Cancer Res. 12 (2006) 1794-1803
33. Gillet J.P., Efferth T., Steinbach D., Hamels J., de Longueville F., Bertholet V., and Remacle J. Microarray-based detection of multidrug resistance in human tumor cells by expression profiling of ATP-binding cassette transporter genes. Cancer Res. 64 (2004) 8987-8993
34. Giovannetti E., Laan A.C., Vasile E., Tibaldi C., Nannizzi S., Ricciardi S., Falcone A., Danesi R., and Peters G.J. Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples. Nucleosides Nucleotides Nucleic Acids 27 (2008) 720-725
35. Goan Y.G., Zhou B., Hu E., Mi S., and Yen Y. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2, 2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res. 59 (1999) 4204-4207
36. Goetz M.P., Rae J.M., Suman V.J., Safgren S.L., Ames M.M., Visscher D.W., Reynolds C., Couch F.J., Lingle W.L., Flockhart D.A., Desta Z., Perez E.A., and Ingle J.N. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 23 (2005) 9312-9318
37. Gonzalez F.J., and Nebert D.W. Evolution of the P450 gene superfamily: animal-plant 'warfare', molecular drive and human genetic differences in drug oxidation. Trends Genet. 6 (1990) 182-186
38. Gorlov I.P., Gorlova O.Y., Sunyaev S.R., Spitz M.R., and Amos C.I. Shifting paradigm of association studies: value of rare single-nucleotide polymorphisms. Am. J. Hum. Genet. 82 (2008) 100-112
39. Gottesman M.M., Fojo T., and Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev., Cancer 2 (2002) 48-58
40. Goyette P., Sumner J.S., Milos R., Duncan A.M., Rosenblatt D.S., Matthews R.G., and Rozen R. Human methylenetetrahydrofolate reductase: isolation of cDNA mapping and mutation identification. Nat. Genet. 7 (1994) 551
41. Guillem V.M., Collado M., Terol M.J., Calasanz M.J., Esteve J., Gonzalez M., Sanzo C., Nomdedeu J., Bolufer P., Lluch A., and Tormo M. Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies. Leukemia 21 (2007) 1413-1422
42. Harrison L., Ascione G., Menninger J.C., Ward D.C., and Demple B. Human apurinic endonuclease gene (APE): structure and genomic mapping (chromosome 14q11.2-12). Hum. Mol. Genet. 1 (1992) 677-680
43. Higgins C.F. ABC transporters: from microorganisms to man. Annu. Rev. Cell Biol. 8 (1992) 67-113
44. Hoeijmakers J.H. Genome maintenance mechanisms for preventing cancer. Nature 411 (2001) 366-374
45. Hombach-Klonisch S., Paranjothy T., Wiechec E., Pocar P., Mustafa T., Seifert A., Zahl C., Gerlach K.L., Biermann K., Steger K., Hoang-Vu C., Schulze-Osthoff K., and Los M. Cancer stem cells as targets for cancer therapy: selected cancers as examples. Arch. Immunol. Ther. Exp. (Warsz.) 56 (2008) 165-180
46. Huebner C., Petermann I., Browning B.L., Shelling A.N., and Ferguson L.R. Triallelic single nucleotide polymorphisms and genotyping error in genetic epidemiology studies: MDR1 (ABCB1) G2677/T/A as an example. Cancer Epidemiol. Biomarkers Prev. 16 (2007) 1185-1192
47. Huggins C., and Fukunishi R. Induced protection of adrenal cortex against 7, 12-dimethylbenz(alpha)anthracene. Influence of ethionine. Induction of menadione reductase. Incorporation of thymidine-H3. J. Exp. Med. 119 (1964) 923-942
48. Ingle J.N. Pharmacogenomics of tamoxifen and aromatase inhibitors. Cancer 112 (2008) 695-699
49. International HapMap Consortium. The International HapMap Project. Nature 426 (2003) 789-796
50. Jaremko M., Justenhoven C., Schroth W., Abraham B.K., Fritz P., Vollmert C., Illig T., Simon W., Schwab M., and Brauch H. Polymorphism of the DNA repair enzyme XRCC1 is associated with treatment prediction in anthracycline and cyclophosphamide/methotrexate/5-fluorouracil-based chemotherapy of patients with primary invasive breast cancer. Pharmacogenet. Genom. 17 (2007) 529-538
51. Jeffreys A.J., Neumann R., Panayi M., Myers S., and Donnelly P. Human recombination hot spots hidden in regions of strong marker association. Nat. Genet. 37 (2005) 601-606
52. Kafka A., Sauer G., Jaeger C., Grundmann R., Kreienberg R., Zeillinger R., and Deissler H. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int. J. Oncol. 22 (2003) 1117-1121
53. Kim R.B. MDR1 single nucleotide polymorphisms: multiplicity of haplotypes and functional consequences. Pharmacogenetics 12 (2002) 425-427
54. Kivisto K.T., Kroemer H.K., and Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br. J. Clin. Pharmacol. 40 (1995) 523-530
55. Kiyotani K., Mushiroda T., Sasa M., Bando Y., Sumitomo I., Hosono N., Kubo M., Nakamura Y., and Zembutsu H. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci. 99 (2008) 995-999
56. Klein I., Sarkadi B., and Varadi A. An inventory of the human ABC proteins. Biochim. Biophys. Acta 1461 (1999) 237-262
57. Klonisch T., Wiechec E., Hombach-Klonisch S., Ande S.R., Wesselborg S., Schulze-Osthoff K., and Los M. Cancer stem cell markers in common cancers - therapeutic implications. Trends Mol. Med. 14 (2008) 450-460
58. Koepsell H., Schmitt B.M., and Gorboulev V. Organic cation transporters. Rev. Physiol. Biochem. Pharmacol. 150 (2003) 36-90
59. Koepsell H., Lips K., and Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm. Res. 24 (2007) 1227-1251
60. Lal S., Wong Z.W., Jada S.R., Xiang X., Chen Shu X., Ang P.C., Figg W.D., Lee E.J., and Chowbay B. Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. Pharmacogenomics 8 (2007) 567-575
61. Lal S., Wong Z.W., Sandanaraj E., Xiang X., Ang P.C., Lee E.J., and Chowbay B. Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Cancer Sci. 99 (2008) 816-823
62. Li W.H., and Sadler L.A. Low nucleotide diversity in man. Genetics 129 (1991) 513-523
63. Liska D.J. The detoxification enzyme systems. Altern. Med. Rev. 3 (1998) 187-198
64. Marsh S., Somlo G., Li X., Frankel P., King C.R., Shannon W.D., McLeod H.L., and Synold T.W. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J. 7 (2007) 362-365
65. Mohrenweiser H.W., Carrano A.V., Fertitta A., Perry B., Thompson L.H., Tucker J.D., and Weber C.A. Refined mapping of the three DNA repair genes, ERCC1, ERCC2, and XRCC1, on human chromosome 19. Cytogenet. Cell Genet. 52 (1989) 11-14
66. Nakajima M., Komagata S., Fujiki Y., Kanada Y., Ebi H., Itoh K., Mukai H., Yokoi T., and Minami H. Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. Pharmacogenet. Genom. 17 (2007) 431-445
67. Nebert D.W. Pharmacogenetics and human cancer. IARC Sci. Publ. (1982) 365-380
68. Nickerson D.A., Taylor S.L., Weiss K.M., Clark A.G., Hutchinson R.G., Stengard J., Salomaa V., Vartiainen E., Boerwinkle E., and Sing C.F. DNA sequence diversity in a 9.7-kb region of the human lipoprotein lipase gene. Nat. Genet. 19 (1998) 233-240
69. Nolin T.D., Naud J., Leblond F.A., and Pichette V. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin. Pharmacol. Ther. 83 (2008) 898-903
70. Nordgard S.H., Alnaes G.I., Hihn B., Lingjaerde O.C., Liestol K., Tsalenko A., Sorlie T., Lonning P.E., Borresen-Dale A.L., and Kristensen V.N. Pathway based analysis of SNPs with relevance to 5-FU therapy: relation to intratumoral mRNA expression and survival. Int. J. Cancer 123 (2008) 577-585
71. Nowell S., Sweeney C., Winters M., Stone A., Lang N.P., Hutchins L.F., Kadlubar F.F., and Ambrosone C.B. Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. J. Natl. Cancer Inst. 94 (2002) 1635-1640
72. Okabe M., Unno M., Harigae H., Kaku M., Okitsu Y., Sasaki T., Mizoi T., Shiiba K., Takanaga H., Terasaki T., Matsuno S., Sasaki I., Ito S., and Abe T. Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochem. Biophys. Res. Commun. 333 (2005) 754-762
73. O'Mahony M.S., and Woodhouse K.W. Age, environmental factors and drug metabolism. Pharmacol. Ther. 61 (1994) 279-287
74. Parker N.J., Begley C.G., and Fox R.M. Human gene for the large subunit of ribonucleotide reductase (RRM1): functional analysis of the promoter. Genomics 27 (1995) 280-285
75. Prescott L.F., Forrest J.A., Adjepon-Yamoah K.K., and Finlayson N.D. Drug metabolism in liver disease. J. Clin. Pathol. Suppl. (R. Coll. Pathol.) 9 (1975) 62-65
76. Pullarkat S.T., Stoehlmacher J., Ghaderi V., Xiong Y.P., Ingles S.A., Sherrod A., Warren R., Tsao-Wei D., Groshen S., and Lenz H.J. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 1 (2001) 65-70
77. Quinney S.K., Sanghani S.P., Davis W.I., Hurley T.D., Sun Z., Murry D.J., and Bosron W.F. Hydrolysis of capecitabine to 5′-deoxy-5-fluorocytidine by human carboxylesterases and inhibition by loperamide. J. Pharmacol. Exp. Ther. 313 (2005) 1011-1016
78. Raida M., Schwabe W., Hausler P., Van Kuilenburg A.B., Van Gennip A.H., Behnke D., and Hoffken K. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin. Cancer Res. 7 (2001) 2832-2839
79. Rajkumar T., Samson M., Rama R., Sridevi V., Mahji U., Swaminathan R., and Nancy N.K. TGFbeta1 (Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women and TGFbeta1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemo-radiotherapy. Breast Cancer Res. Treat. 112 (2008) 81-87
80. Ramana C.V., Boldogh I., Izumi T., and Mitra S. Activation of apurinic/apyrimidinic endonuclease in human cells by reactive oxygen species and its correlation with their adaptive response to genotoxicity of free radicals. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 5061-5066
81. Rha S.Y., Jeung H.C., Choi Y.H., Yang W.I., Yoo J.H., Kim B.S., Roh J.K., and Chung H.C. An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients. Oncologist 12 (2007) 622-630
82. Ribelles N., Lopez-Siles J., Sanchez A., Gonzalez E., Sanchez M.J., Carabantes F., Sanchez-Rovira P., Marquez A., Duenas R., Sevilla I., and Alba E. A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression. Curr. Drug Metab. 9 (2008) 336-343
83. Ross D., Kepa J.K., Winski S.L., Beall H.D., Anwar A., and Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem. Biol. Interact. 129 (2000) 77-97
84. Rustum Y.M., Harstrick A., Cao S., Vanhoefer U., Yin M.B., Wilke H., and Seeber S. Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J. Clin. Oncol. 15 (1997) 389-400
85. Sai K., Kaniwa N., Itoda M., Saito Y., Hasegawa R., Komamura K., Ueno K., Kamakura S., Kitakaze M., Shirao K., Minami H., Ohtsu A., Yoshida T., Saijo N., Kitamura Y., Kamatani N., Ozawa S., and Sawada J. Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics 13 (2003) 741-757
86. Saito S., Iida A., Sekine A., Miura Y., Ogawa C., Kawauchi S., Higuchi S., and Nakamura Y. Three hundred twenty-six genetic variations in genes encoding nine members of ATP-binding cassette, subfamily B (ABCB/MDR/TAP), in the Japanese population. J. Hum. Genet. 47 (2002) 38-50
87. Schilsky R.L. Biochemical and clinical pharmacology of 5-fluorouracil. Oncology (Willist. Park N. Y.) 12 (1998) 13-18
88. Siegel D., Gustafson D.L., Dehn D.L., Han J.Y., Boonchoong P., Berliner L.J., and Ross D. NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger. Mol. Pharmacol. 65 (2004) 1238-1247
89. Sjoqvist F. The past, present and future of clinical pharmacology. Eur. J. Clin. Pharmacol. 55 (1999) 553-557
90. Smith I.E. Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy. J. Steroid Biochem. Mol. Biol. 86 (2003) 289-293
91. Smith I.E., and Dowsett M. Aromatase inhibitors in breast cancer. N. Engl. J. Med. 348 (2003) 2431-2442
92. Sohn K.J., Croxford R., Yates Z., Lucock M., and Kim Y.I. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J. Natl. Cancer Inst. 96 (2004) 134-144
93. Stearns V., and Rae J.M. Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?. Expert Rev. Mol. Med. 10 (2008) e34
94. Stearns V., Johnson M.D., Rae J.M., Morocho A., Novielli A., Bhargava P., Hayes D.F., Desta Z., and Flockhart D.A. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl. Cancer Inst. 95 (2003) 1758-1764
95. Stearns V., Davidson N.E., and Flockhart D.A. Pharmacogenetics in the treatment of breast cancer. Pharmacogenomics J. 4 (2004) 143-153
96. Steed H., and Sawyer M.B. Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel. Pharmacogenomics 8 (2007) 803-815
97. Sugiyama E., Kaniwa N., Kim S.R., Kikura-Hanajiri R., Hasegawa R., Maekawa K., Saito Y., Ozawa S., Sawada J., Kamatani N., Furuse J., Ishii H., Yoshida T., Ueno H., Okusaka T., and Saijo N. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J. Clin. Oncol. 25 (2007) 32-42
98. Takimoto C.H., Lu Z.H., Zhang R., Liang M.D., Larson L.V., Cantilena Jr. L.R., Grem J.L., Allegra C.J., Diasio R.B., and Chu E. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin. Cancer Res. 2 (1996) 477-481
99. Thussbas C., Nahrig J., Streit S., Bange J., Kriner M., Kates R., Ulm K., Kiechle M., Hoefler H., Ullrich A., and Harbeck N. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J. Clin. Oncol. 24 (2006) 3747-3755
100. Toyama T., Zhang Z., Nishio M., Hamaguchi M., Kondo N., Iwase H., Iwata H., Takahashi S., Yamashita H., and Fujii Y. Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res. 9 (2007) R34
101. van Kuilenburg A.B. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur. J. Cancer 40 (2004) 939-950
102. van Kuilenburg A.B., Haasjes J., Richel D.J., Zoetekouw L., Van Lenthe H., De Abreu R.A., Maring J.G., Vreken P., and van Gennip A.H. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin. Cancer Res. 6 (2000) 4705-4712
103. van Kuilenburg A.B., Muller E.W., Haasjes J., Meinsma R., Zoetekouw L., Waterham H.R., Baas F., Richel D.J., and van Gennip A.H. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14 + 1G>A mutation causing DPD deficiency. Clin. Cancer Res. 7 (2001) 1149-1153
104. Villafranca E., Okruzhnov Y., Dominguez M.A., Garcia-Foncillas J., Azinovic I., Martinez E., Illarramendi J.J., Arias F., Martinez Monge R., Salgado E., Angeletti S., and Brugarolas A. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J. Clin. Oncol. 19 (2001) 1779-1786
105. Wasternack C. Degradation of pyrimidines and pyrimidine analogs-pathways and mutual influences. Pharmacol. Ther. 8 (1980) 629-651
106. Wegman P., Vainikka L., Stal O., Nordenskjold B., Skoog L., Rutqvist L.E., and Wingren S. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res. 7 (2005) R284-R290
107. Wong G.K., Yang Z., Passey D.A., Kibukawa M., Paddock M., Liu C.R., Bolund L., and Yu J. A population threshold for functional polymorphisms. Genome Res. 13 (2003) 1873-1879
108. Woodhouse K.W., and Wynne H.A. Age-related changes in liver size and hepatic blood flow. The influence on drug metabolism in the elderly. Clin. Pharmacokinet. 15 (1988) 287-294
109. Wu M.H., Yan B., Humerickhouse R., and Dolan M.E. Irinotecan activation by human carboxylesterases in colorectal adenocarcinoma cells. Clin. Cancer Res. 8 (2002) 2696-2700
110. Xu Y., Yao L., Ouyang T., Li J., Wang T., Fan Z., Lin B., Lu Y., and Xie Y. p53 codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin. Cancer Res. 11 (2005) 7328-7333
111. Zhu Y., Spitz M.R., Amos C.I., Lin J., Schabath M.B., and Wu X. An evolutionary perspective on single-nucleotide polymorphism screening in molecular cancer epidemiology. Cancer Res. 64 (2004) 2251-2257